Who are tocilizumab or sarilumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Roactemra, Ro-Actemra, Actemra(EU-licensed), MIL62, Placebo to GSK3196165/ Sarilumab, EU-approved RoActemra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tocilizumab-or-sarilumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

tocilizumab or sarilumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tocilizumab or sarilumab (tocilizumab-or-sarilumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Immunology.

marketed monoclonal antibody interleukin-6 receptor Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

tocilizumab or sarilumab (tocilizumab-or-sarilumab) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tocilizumab or sarilumab TARGET	tocilizumab-or-sarilumab	Pfizer	marketed	monoclonal antibody	interleukin-6 receptor
Roactemra	tocilizumab	Roche	marketed	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
Ro-Actemra	Ro-Actemra	Medical University of Vienna	marketed	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
Actemra(EU-licensed)	Actemra(EU-licensed)	Bio-Thera Solutions	phase 3	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
MIL62	MIL62	Beijing Mabworks Biotech Co., Ltd.	phase 3	IL-6 receptor antagonist monoclonal antibody	IL-6R (Interleukin-6 receptor)
Placebo to GSK3196165/ Sarilumab	Placebo to GSK3196165/ Sarilumab	GlaxoSmithKline	phase 3	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
EU-approved RoActemra	EU-approved RoActemra	Fresenius Kabi SwissBioSim GmbH	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6R (Interleukin-6 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tocilizumab or sarilumab — Competitive Intelligence Brief. https://druglandscape.com/ci/tocilizumab-or-sarilumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab